| 000 | 02506 a2200685 4500 | ||
|---|---|---|---|
| 005 | 20250515095552.0 | ||
| 264 | 0 | _c20080416 | |
| 008 | 200804s 0 0 eng d | ||
| 022 | _a1569-8041 | ||
| 024 | 7 |
_a10.1093/annonc/mdm554 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aChi, K N | |
| 245 | 0 | 0 |
_aA phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. _h[electronic resource] |
| 260 |
_bAnnals of oncology : official journal of the European Society for Medical Oncology _cApr 2008 |
||
| 300 |
_a746-51 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAngiogenesis Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Hormonal _xtherapeutic use |
| 650 | 0 | 4 |
_aBenzenesulfonates _xadministration & dosage |
| 650 | 0 | 4 |
_aBiomarkers, Tumor _xanalysis |
| 650 | 0 | 4 | _aCanada |
| 650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aDrug Resistance, Neoplasm |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunohistochemistry |
| 650 | 0 | 4 | _aKaplan-Meier Estimate |
| 650 | 0 | 4 | _aLymphatic Metastasis |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasms, Hormone-Dependent _xblood supply |
| 650 | 0 | 4 |
_aNeovascularization, Pathologic _xdrug therapy |
| 650 | 0 | 4 |
_aNiacinamide _xanalogs & derivatives |
| 650 | 0 | 4 | _aPhenylurea Compounds |
| 650 | 0 | 4 |
_aProstate-Specific Antigen _xblood |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xblood supply |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aPyridines _xadministration & dosage |
| 650 | 0 | 4 | _aSorafenib |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aEllard, S L | |
| 700 | 1 | _aHotte, S J | |
| 700 | 1 | _aCzaykowski, P | |
| 700 | 1 | _aMoore, M | |
| 700 | 1 | _aRuether, J D | |
| 700 | 1 | _aSchell, A J | |
| 700 | 1 | _aTaylor, S | |
| 700 | 1 | _aHansen, C | |
| 700 | 1 | _aGauthier, I | |
| 700 | 1 | _aWalsh, W | |
| 700 | 1 | _aSeymour, L | |
| 773 | 0 |
_tAnnals of oncology : official journal of the European Society for Medical Oncology _gvol. 19 _gno. 4 _gp. 746-51 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/annonc/mdm554 _zAvailable from publisher's website |
| 999 |
_c17570966 _d17570966 |
||